PP Defence Therapeutics Related News
Defence Therapeutics’ mRNA cancer vaccine testing begins
Canadian biopharmaceutical specialist Defence Therapeutics has announced that testing of its revolutionary AccumTM-linked mRNA cancer vaccine has started.
The performance of Defence’s AccumTM mRNA cancer...
Defence Therapeutics successfully develops ACCUMTM -mRNA cancer vaccine
Canadian biopharmaceutical pioneer Defence Therapeutics has revealed it has successfully conjugated mRNA molecules to AccumTM – a significant breakthrough that looks to enhance the...
Defence to perform final AccuTOXTM preclinical study before Phase I cancer trial
Defence Therapeutics has announced it is performing a final preclinical study to validate the efficacy of AccuTOXTM combined with immune-checkpoint inhibitors before initiating a...
Defence Therapeutics and Orano agree to collaborate on radio-immuno-conjugates
Defence Therapeutics Inc. is pleased to announce that they have signed a collaboration agreement with Orano to develop next-generation radio-immuno-conjugates using their intracellular targeting...
Defence advances to phase I clinical trials of the Accum technology
Defence Therapeutics Inc. is pleased to update its stakeholders on its completed achievements and outline the future milestones for AccumTM set for 2023.
Over the...
Defence work with City of Hope in filing a new AccuTOX cancer programme
Defence Therapeutics has teamed up with City of Hope to submit an application for the clinical trialling of their AccuTOX TM technology.
The Canadian biopharmaceutical...
Defence Therapeutics begins manufacturing of it’s ARM vaccine
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the start...
Defence Therapeutics begin toxicology study on intranasal AccutoxTM
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start...
Defence Therapeutics has melanoma vaccine validated
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation...
Defence Therapeutics has US patent accepted for Accum
Defence Therapeutics Inc, a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate...
Defence Therapeutics launch Accum-mRNA vaccine programme
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement...
Defence’s novel Accutox intranasal reduces 50% of cancer nodules
Defence Therapeutics, a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, has just completed a pre-clinical study using...
Defence Therapeutics are using Accum technology in mRNA vaccines
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is currently working on combining its...
Defence Therapeutics to begin phase 1 trial for new anti-cancer treatment
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful...
Defence’s successful study on the ACCUVAC-PT007 vaccine
Defence Therapeutics Inc. has announced its successful study on its ACCUVAC-PT007 vaccine, which targets cervical cancer.
Defence Therapeutics Inc. a Canadian biopharmaceutical company specialised in...
Defence Therapeutics applies Accum technology to anti-cancer vaccine
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is initiating a new research and...
Defence Therapeutics launches new AccuTOX lung cancer treatment
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the start...
Defence Therapeutics have been granted patents for their antibody-drug conjugate technology
Defence Therapeutics is pleased to announce that notices of allowance have been issued by the Japanese and Israeli Patent Offices for patent application no....
Enhancing treatment efficacy and antigen delivery with Accum
Defence Therapeutics outlines the potential of their innovative AccumTM technology to improve intracellular antigen delivery and ultimately enhance treatments for cancer and infectious diseases.
Defence...
Accum A1-reprogrammed vaccine cured 80% of animals with pre-established lymphoma
Defence Therapeutics Inc, a Canadian biopharmaceutical company specialising in developing immune-oncology vaccines and drug delivery technologies, are pleased to report that Defence’s novel vaccine...